The long term goal is to elucidate the processes by which mitogenic signals are relayed intracellularly, and to apply this information to understanding how normal growth control is deregulated enabling the progression of lung cancer. Among the differences between normal and tumor lung cells is that the tumor cells secrete increased concentrations of growth factors, which in some instances drive the increased growth rate of the tumors. Thus one of the mechanisms by which normal lung tissue becomes tumorigenic involves increased concentrations of growth factors. However, increased concentrations of growth factors alone are probably not enough to cause lung tumors, since chronic stimulation of tissue culture cells with high levels of growth factors does not usually lead to transformation. More often, cells become transformed when they overexpress and/or harbor mutations within their growth factor receptors. The short-term goal, to be addressed in this research proposal, is to test whether progression of normal lung cells to the malignant state involves both the increased production of growth factors and the mutation and/or overexpression of growth factor receptors. The first specific aim will define the incidence of overexpression and mutation of known growth factor receptors, while the second specific aim will focus on identifying novel lung-specific receptor tyrosine kinases. In the third specific aim, the biological significance of the first two specific aims will be tested. The mutant and novel receptors will be expressed in normal lung tissue to test whether they act as oncogenes. The effect of growth factor stimulation on the ability to transform will also be determined. Finally, we will test the contribution of the identified growth factor receptors to the progression of lung cells from the premalignant to the tumorigenic state. The direct benefit of understanding the role of growth factors and their receptors in the progression of lung tumors will significantly contribute to both prognosis of the stage of a lung tumor, as well as the treatment and management of lung tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA058187-01
Application #
3796265
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308
Ghosh, Moumita; Miller, York E; Vandivier, R William et al. (2018) Reply to Sohal: Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:1645-1646
Ghosh, Moumita; Miller, York E; Nakachi, Ichiro et al. (2018) Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:885-896
Farago, Anna F; Taylor, Martin S; Doebele, Robert C et al. (2018) Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol 2018:
He, Yayi; Liu, Sangtian; Mattei, Jane et al. (2018) The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther 12:981-986
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503

Showing the most recent 10 out of 435 publications